FRACTION-RCC: innovative, high-throughput assessment of nivolumab plus ipilimumab (N plus I) for treatment-refractory advanced renal cell carcinoma (aRCC)W. Loidl,T. K. Choueiri,H. Kluger,S. George,S. S. Tykodi,T. M. Kuzel,R. Perets,S. Nair,G. Procopio,M. Carducci,V. Castonguay,E. Folefac,C. -H. Lee,S. J. Hotte,W. H. Miller,S. S. Saggi,D. Gold,R. J. Motzer,B. EscudierJOURNAL OF CLINICAL ONCOLOGY（2020）引用 35|浏览58暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
